Video
Dr. Ribas on Anti-PD-1 Agent Lambrolizumab in Melanoma
Author(s):
Antoni Ribas, MD, PhD, from UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.
Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.
Clinically meaningful activity was observed in a substantial number of patients in the trial, Ribas explains. The overall response rate by RECIST criteria was 38% with 90% of patients experiencing durable responses. At the highest dose, response was 52%. Most of the adverse events with lambrolizumab were minimal, Ribas suggests.
<<<
%20(2)%201-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
